A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Overview
- Phase
- Phase 3
- Intervention
- Idelalisib
- Conditions
- Chronic Lymphocytic Leukemia
- Sponsor
- Gilead Sciences
- Enrollment
- 261
- Locations
- 78
- Primary Endpoint
- Progression-Free Survival
- Status
- Terminated
- Last Updated
- 6 years ago
Overview
Brief Summary
The primary objective of this study is to evaluate the effect of the addition of idelalisib to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Adults with previously treated recurrent CLL who have measurable lymphadenopathy
- •Require therapy for CLL
- •Have experienced CLL progression \< 24 months since the completion of the last prior therapy
- •Have disease that is not refractory to ofatumumab
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Exclusion Criteria
- Not provided
Arms & Interventions
Idelalisib+ofatumumab
Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.
Intervention: Idelalisib
Idelalisib+ofatumumab
Randomized Initial Therapy (24 weeks): Idelalisib + ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 1000 mg weekly for 7 weeks, and then 1000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Idelalisib 150 mg tablets twice daily until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.
Intervention: Ofatumumab
Ofatumumab
Randomized Initial Therapy (24 weeks): Ofatumumab for a total of 12 infusions (300 mg on Day 1, followed by 2000 mg weekly for 7 weeks, and then 2000 mg every 4 weeks for 4 doses) Continuing Therapy/Observation: Observation until the earliest of participant withdrawal from study, definitive progression of CLL, intolerable idelalisib-related toxicity, pregnancy or initiation of breast feeding, substantial noncompliance with study procedures, or study discontinuation. Long-Term Follow-up: Participants were followed for up to 5 years. Information on medical status, anti-tumor treatments, secondary malignancies, and survival status were collected annually during a routine clinic visit or other contact, such as telephone.
Intervention: Ofatumumab
Outcomes
Primary Outcomes
Progression-Free Survival
Time Frame: Randomization to End of Study (up to 60 months)
Progression-free survival (PFS) was defined as the interval from randomization to the earlier of the first documentation of definitive disease progression or death from any cause. Definitive disease progression was CLL progression based on standard criteria (other than lymphocytosis alone) as defined by the 2008 update of the International Workshop on CLL guidelines, ie, appearance of any new lesion; increase by ≥ 50% in the sum of the products of the perpendicular diameters of measured lymph nodes (SPD); new or ≥ 50% enlargement of liver or spleen; transformation to a more aggressive histology (eg, Richter's or prolymphocytic transformation); reduction in the number of blood cells (cytopenia) attributable to CLL. PFS was analyzed using Kaplan-Meier (KM) estimates.
Secondary Outcomes
- Lymph Node Response Rate(Randomization to End of Study (up to 60 months))
- Complete Response Rate(Randomization to End of Study (up to 60 months))
- Overall Response Rate(Randomization to End of Study (up to 60 months))
- Overall Survival(Randomization to Last Long-Term Follow-Up Visit (up to maximum of 5 years))
- Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation(Randomization to End of Study (up to 60 months))